Aberrations in Lipid Expression and Metabolism in Psoriasis
Abstract
:1. Introduction
2. Associations between Psoriasis and Metabolic Disorders
2.1. Links between Psoriasis and Obesity
2.2. Links between Psoriasis and Atherosclerosis
2.3. Links between Psoriasis and Nonalcoholic Fatty Liver Disease
3. Aberrations in Lipid Expression in Psoriatic Patients
3.1. Lipoprotein Receptors
3.2. Peroxisome Proliferator-Activated Receptors
4. Aberrations in Lipid Metabolism in Psoriatic Patients
4.1. Lipids in Psoriatic Patients’ Skin
4.2. Lipids in Psoriatic Patients’ Blood
4.2.1. Lipid Profile in Psoriatic Patients’ Blood
4.2.2. Phospholipids
4.2.3. Adipokines in Psoriatic Patients’ Blood
4.2.4. Fatty Acid-Binding Proteins in Psoriatic Patients
4.3. Lipids in Psoriatic Patients’ Biliary Metabolism
5. The influence of Lipid-Lowering Drugs on Psoriasis
6. The Influence of Systemic Antipsoriatic Agents on Lipidemia
7. Conclusions
8. Materials and Methods
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
BMI | body mass index |
CD | cluster antigen |
CMDs | cardiometabolic disorders |
DM | diabetes mellitus |
FABPs | fatty acid-binding proteins |
FFA | free fatty acids |
HDL | high-density lipoprotein |
HLA | human leukocyte antigen |
HMG-CoA | 3-hydroxy-3-methylo-glutarylo-coenzyme A |
IL | interleukin |
INFγ | interferon gamma |
LDL | low-density lipoprotein |
LRP | lipoprotein-related receptors |
LOX-1 | lectin-type ox-LDL receptor |
LPA | lysophosphatidic acid |
LPC | lysophosphatidylcholine |
MS | metabolic syndrome |
MUFA | monounsaturated fatty acids |
NAFLD | nonalcoholic fatty liver disease |
NB-UVB | Narrowband—ultraviolet B |
ox-LDL | oxidized modified low-density lipoproteins |
PA | phosphatidic acid |
PASI | psoriasis activity and severity index |
PCSK9 | proprotein convertase subtilisin/kexin type 9 |
PDE4 | phosphodiesterase 4 |
PI | phosphatidylinositol |
PPARs | peroxisome proliferator-activated receptors |
PSO | psoriasis |
PUFA | polyunsaturated fatty acids |
SFAs | saturated fatty acids |
sLOX-1 | soluble lectinlike oxidized low-density lipoprotein receptor-1 |
SR-B1 | scavenger receptor class B type 1 |
TNFα | tumor necrosis factor-alpha |
VLDL | very-low-density lipoprotein |
ZAG | zinc-α2-glycoprotein |
References
- Shih, C.M.; Chen, C.C.; Chu, C.K.; Wang, K.H.; Huang, C.Y.; Lee, A.W. The Roles of Lipoprotein in Psoriasis. Int. J. Mol. Sci. 2020, 2, 859. [Google Scholar] [CrossRef] [Green Version]
- Hirotsu, C.; Rydlewski, M.; Araújo, M.S.; Tufik, S.; Andersen, M.L. Sleep loss and cytokines levels in an experimental model of psoriasis. PLoS ONE 2012, 7, e51183. [Google Scholar] [CrossRef] [Green Version]
- Reich, A.; Adamski, Z.; Chodorowska, G.; Kaszuba, A.; Krasowska, D.; Lesiak, A.; Maj, J.; Narbutt, J.; Osmola-Mańkowska, A.J.; Owczarczyk-Saczonek, A.; et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Dermatol. Rev. 2020, 107, 92–109. [Google Scholar] [CrossRef]
- Takeshita, J.; Grewal, S.; Langan, S.M.; Mehta, N.N.; Ogdie, A.; Van Voorhees, A.S.; Gelfand, J.M. Psoriasis and comorbid diseases: Epidemiology. J. Am. Acad. Dermatol. 2017, 76, 377–390. [Google Scholar] [CrossRef] [Green Version]
- Nowowiejska, J.; Baran, A.; Lewoc, M.; Grabowska, P.; Kaminski, T.W.; Flisiak, I. The Assessment of Risk and Predictors of Sleep Disorders in Patients with Psoriasis—A Questionnaire-Based Cross-Sectional Analysis. J. Clin. Med. 2021, 10, 664. [Google Scholar] [CrossRef] [PubMed]
- Baran, A.; Nowowiejska, J.; Krahel, J.A.; Kaminski, T.W.; Maciaszek, M.; Flisiak, I. Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis. Int. J. Mol. Sci. 2020, 21, 4594. [Google Scholar] [CrossRef] [PubMed]
- Zeng, C.; Wen, B.; Hou, G.; Lei, L.; Mei, Z.; Jia, X.; Chen, X.; Zhu, W.; Li, J.; Kuang, Y.; et al. Lipidomics profiling reveals the role of glycerophospholipid metabolism in psoriasis. Gigascience 2017, 6, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nowowiejska, J.; Baran, A.; Flisiak, I. Psoriasis and cardiometabolic disorders. Dermatol. Rev. 2020, 107, 508–520. [Google Scholar] [CrossRef]
- Gisondi, P.; Fostini, A.C.; Fossà, I.; Girolomoni, G.; Targher, G. Psoriasis and the metabolic syndrome. Clin. Dermatol. 2018, 36, 21–28. [Google Scholar] [CrossRef]
- Gonzalez-Cantero, A.; Gonzalez-Cantero, J.; Sanchez-Moya, A.I.; Perez-Hortet, C.; Arias-Santiago, S.; Schoendorff-Ortega, C.; Gonzalez-Calvin, J.L. Subclinical atherosclerosis in psoriasis. Usefulness of femoral artery ultrasound for the diagnosis, and analysis of its relationship with insulin resistance. PLoS ONE 2019, 14, e0211808. [Google Scholar]
- Chait, A.; den Hartigh, L.J. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front. Cardiovasc. Med. 2020, 7, 22. [Google Scholar] [CrossRef] [Green Version]
- Krasowska, D.; Adamczyk, M. The impact of obesity on psoriasis. Dermatol. Rev. 2016, 103, 303–308. [Google Scholar] [CrossRef] [Green Version]
- Coto-Segura, P.; González-Lara, L.; Eiris, N.; Santos-Juanes, J.; Queiro, R.; Coto, E. Effect of the FTO rs9930506 polymorphism on obesity and the main clinical outcomes in patients with psoriasis. Br. J. Dermatol. 2014, 171, 917–919. [Google Scholar] [CrossRef] [PubMed]
- Jin, Y.; Zhang, F.; Yang, S.; Kong, Y.; Xiao, F.; Hou, Y.; Fan, X.; Zhang, X. Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population. J. Dermatol. Sci. 2008, 52, 123–129. [Google Scholar] [CrossRef]
- Wong, Y.; Nakamizo, S.; Tan, K.J.; Kabashima, K. An Update on the Role of Adipose Tissues in Psoriasis. Front. Immunol. 2019, 10, 1507. [Google Scholar] [CrossRef] [PubMed]
- Kovács, D.; Fazekas, F.; Oláh, A.; Törőcsik, D. Adipokines in the Skin and in Dermatological Diseases. Int. J. Mol. Sci. 2020, 21, 9048. [Google Scholar] [CrossRef]
- Baran, A.; Flisiak, I.; Myśliwiec, H.; Chodynicka, B. Role of adiponectin in psoriasis. Dermatol. Rev. 2010, 97, 413–416. [Google Scholar]
- Baran, A.; Flisiak, I.; Jaroszewicz, J.; Świderska, M. Effect of psoriasis activity on serum adiponectin and leptin levels. Adv. Dermatol. Alergol. 2015, 32, 101–106. [Google Scholar] [CrossRef] [Green Version]
- Rognoni, A.; Cavallino, C.; Veia, A.; Bacchini, S.; Rosso, R.; Facchini, M.; Secco, G.G.; Lupi, A.; Nardi, F.; Rametta, F.; et al. Pathophysiology of Atherosclerotic Plaque Development. Cardiovasc. Hematol. Agents Med. Chem. 2015, 13, 10–13. [Google Scholar] [CrossRef]
- Komorowska, O.R.; Szczerkowska-Dobosz, A.; Purzycka-Bohdan, D.; Rawicz-Zegrzda, D.; Dudziak, M. Psoriasis as a risk factor of cardiovascular diseases. Dermatol. Rev. 2014, 101, 500–506. [Google Scholar] [CrossRef] [Green Version]
- Carrascosa, J.M.; Bonanad, C.; Dauden, E.; Botella, R.; Olveira-Martín, A.; Systemic Inflammation in Psoriasis Working Group. Psoriasis and Nonalcoholic Fatty Liver Disease. Actas Dermosifiliogr. 2017, 108, 506–514. [Google Scholar] [CrossRef]
- Mantovani, A.; Gisondi, P.; Lonardo, A.; Targher, G. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? Int. J. Mol. Sci. 2016, 17, 217. [Google Scholar] [CrossRef] [Green Version]
- Gisondi, P.; Bellinato, F.; Girolomoni, G.; Albanesi, C. Pathogenesis of Chronic Plaque Psoriasis and Its Intersection With Cardio-Metabolic Comorbidities. Front. Pharmacol. 2020, 11, 117. [Google Scholar] [CrossRef]
- Ortolan, A.; Lorenzin, M.; Tadiotto, G.; Russo, F.P.; Oliviero, F.; Felicetti, M.; D’Incà, R.; Favero, M.; Piaserico, S.; Doria, A.; et al. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clin. Rheumatol. 2019, 38, 2843–2850. [Google Scholar] [CrossRef] [PubMed]
- Mommaas, M.; Tada, J.; Wijsman, M.C.; Onderwater, J.J.; Vermeer, B.J. Differences in low density lipoprotein receptor expression in the suprabasal layer of normal and psoriatic epidermis. J. Dermatol. Sci. 1990, 1, 15–22. [Google Scholar] [CrossRef]
- Sorokin, A.V.; Domenichiello, A.F.; Dey, A.K.; Yuan, Z.X.; Goyal, A.; Rose, S.M.; Playford, M.P.; Ramsden, C.E.; Mehta, N.N. Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood. J. Investig. Dermatol. 2018, 138, 1518–1528. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duvetorp, A.; Olsen, R.S.; Nyström, H.; Skarstedt, M.; Dienus, O.; Mrowietz, U.; Söderman, J.; Seifert, O. Expression of low-density lipoprotein-related receptors 5 and 6 (LRP5/6) in psoriasis skin. Exp. Dermatol. 2017, 26, 1033–1038. [Google Scholar] [CrossRef]
- McCormick, S.P.A.; Schneider, W.J. Lipoprotein(a) catabolism: A case of multiple receptors. Pathology 2019, 51, 155–164. [Google Scholar] [CrossRef]
- Pasmatzi, E.; Papadionysiou, C.; Monastirli, A.; Badavanis, G.; Tsambaos, D. Galectin 1 in dermatology: Current knowledge and perspectives. Acta Dermatovenerol. Alp. Pannonica Adriat. 2019, 28, 27–31. [Google Scholar] [CrossRef]
- Prens, E.; t Hooft-Benne, K.; Tank, B.; Van Damme, J.; van Joost, T.; Benner, R. Adhesion molecules and IL-1 costimulate T lymphocytes in the autologous MECLR in psoriasis. Arch. Dermatol. Res. 1996, 288, 68–73. [Google Scholar] [CrossRef]
- Dey, A.K.; Gaddipati, R.; Elnabawi, Y.; Ongstad, E.; Goyal, A.; Chung, J.H.; Teague, H.; Rodante, J.A.; Sajja, A.A.; Sorokin, A.V.; et al. Association Between Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 and Coronary Artery Disease in Psoriasis. JAMA Dermatol. 2020, 156, 151–157. [Google Scholar] [CrossRef] [PubMed]
- Shih, C.M.; Huang, C.Y.; Wang, K.H.; Huang, C.Y.; Wei, P.L.; Chang, Y.J.; Hsieh, C.K.; Liu, K.T.; Lee, A.W. Oxidized Low-Density Lipoprotein-Deteriorated Psoriasis Is Associated with the Upregulation of Lox-1 Receptor and Il-23 Expression In Vivo and In Vitro. Int. J. Mol. Sci. 2018, 19, 2610. [Google Scholar] [CrossRef] [Green Version]
- Wang, H.; Yang, G.; Zhang, Q.; Liang, X.; Liu, Y.; Gao, M.; Guo, Y.; Chen, L. Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6. Aging 2020, 12, 19012–19021. [Google Scholar] [CrossRef] [PubMed]
- Han, L.; Shen, W.J.; Bittner, S.; Kraemer, F.B.; Azhar, S. PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. Future Cardiol. 2017, 13, 279–296. [Google Scholar] [CrossRef] [PubMed]
- Baran, A.; Kiluk, P.; Myśliwiec, H.; Flisiak, I. The role of lipids in psoriasis. Dermatol. Rev. 2017, 104, 619–635. [Google Scholar] [CrossRef] [Green Version]
- Kimura, I.; Ichimura, A.; Ohue-Kitano, R.; Igarashi, M. Free Fatty Acid Receptors in Health and Disease. Physiol. Rev. 2020, 100, 171–210. [Google Scholar] [CrossRef]
- Varshney, P.; Narasimhan, A.; Mittal, S.; Malik, G.; Sardana, K.; Saini, N. Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis. Sci. Rep. 2016, 6, 19295. [Google Scholar] [CrossRef] [Green Version]
- Tashakkor, A.Y.; Mancini, G.B. The relationship between skin cholesterol testing and parameters of cardiovascular risk: A systematic review. Can. J. Cardiol. 2013, 29, 1477–1487. [Google Scholar] [CrossRef]
- Van Smeden, J.; Bouwstra, J.A. Stratum Corneum Lipids: Their Role for the Skin Barrier Function in Healthy Subjects and Atopic Dermatitis Patients. Curr. Probl. Dermatol. 2016, 49, 8–26. [Google Scholar]
- Hong, K.K.; Cho, H.R.; Ju, W.C.; Cho, Y.; Kim, N.I. A study on altered expression of serine palmitoyltransferase and ceramidase in psoriatic skin lesion. J. Korean Med. Sci. 2007, 22, 862–867. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tawada, C.; Kanoh, H.; Nakamura, M.; Mizutani, Y.; Fujisawa, T.; Banno, Y.; Seishima, M. Interferon-γ decreases ceramides with long-chain fatty acids: Possible involvement in atopic dermatitis and psoriasis. J. Investig. Dermatol. 2014, 134, 712–718. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Albanesi, C.; Scarponi, C.; Pallotta, S.; Daniele, R.; Bosisio, D.; Madonna, S.; Fortugno, P.; Gonzalvo-Feo, S.; Franssen, J.D.; Parmentier, M.; et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J. Exp. Med. 2009, 206, 249–258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kiluk, P.; Baran, A.; Kaminski, T.; Maciaszek, M.; Flisiak, I. Decreased levels of vaspin and its potential association with cardiometabolic risk in patients with psoriasis: Preliminary results. Adv. Dermatol. Allergol. 2021, 1–9, in press. [Google Scholar]
- Chen, S.H.; Arany, I.; Apisarnthanarax, N.; Rajaraman, S.; Tyring, S.K.; Horikoshi, T.; Brysk, H.; Brysk, M.M. Response of keratinocytes from normal and psoriatic epidermis to interferon-gamma differs in the expression of zinc-alpha(2)-glycoprotein and cathepsin D. FASEB J. 2000, 14, 565–571. [Google Scholar] [CrossRef] [PubMed]
- Ramezani, M.; Zavattaro, E.; Sadeghi, M. Evaluation of serum lipid, lipoprotein, and apolipoprotein levels in psoriatic patients: A systematic review and meta-analysis of case-control studies. Adv. Dermatol. Allergol. 2019, 36, 692–702. [Google Scholar] [CrossRef] [PubMed]
- Pietrzak, A.; Chabros, P.; Grywalska, E.; Pietrzak, D.; Kandzierski, G.; Wawrzycki, B.; Roliński, J.; Gawęda, K.; Krasowska, D. Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis. Adv. Dermatol. Allergol. 2020, 37, 41–45. [Google Scholar] [CrossRef]
- Sieber, J.; Jehle, A.W. Free fatty acids and their metabolism affect function and survival of podocytes. Front. Endocrinol. 2014, 5, 186. [Google Scholar] [CrossRef] [Green Version]
- Myśliwiec, H.; Baran, A.; Harasim-Symbor, E.; Myśliwiec, P.; Milewska, A.J.; Chabowski, A.; Flisiak, I. Serum fatty acid profile in psoriasis and its comorbidity. Arch. Dermatol. Res. 2017, 309, 371–380. [Google Scholar] [CrossRef] [Green Version]
- Owczarczyk-Saczonek, A.; Purzycka-Bohdan, D.; Nedoszytko, B.; Reich, A.; Szczerkowska-Dobosz, A.; Bartosińska, J.; Batycka-Baran, A.; Czajkowski, R.; Dobrucki, I.; Dobrucki, L.; et al. Pathogenesis of psoriasis in the “omic” era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis in psoriasis. Adv. Dermatol. Allergol. 2020, 37, 452–467. [Google Scholar] [CrossRef]
- Ataseven, A.; Kesli, R. Novel inflammatory markers in psoriasis vulgaris: Vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40. G. Ital. Dermatol. Venereol. 2016, 151, 244–250. [Google Scholar]
- McKillop, I.H.; Girardi, C.A.; Thompson, K.J. Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell Signal. 2019, 62, 109336. [Google Scholar] [CrossRef]
- Baran, A.; Kiluk, P.; Maciaszek, M.; Świderska, M.; Flisiak, I. Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis. Arch. Dermatol. Res. 2019, 311, 389–397. [Google Scholar] [CrossRef] [Green Version]
- Baran, A.; Kiluk, P.; Świderska, M.; Maciaszek, M.; Myśliwiec, H.; Flisiak, I. Adipocyte Fatty Acid-Binding Protein as a Novel Marker of Psoriasis and Clinical Response to Acitretin. Lipids 2019, 54, 445–452. [Google Scholar] [CrossRef]
- Baran, A.; Świderska, M.; Bacharewicz-Szczerbicka, J.; Myśliwiec, H.; Flisiak, I. Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis. Lipids 2017, 52, 51–60. [Google Scholar] [CrossRef] [Green Version]
- Sikora, M.; Chrabąszcz, M.; Maciejewski, C.; Zaremba, M.; Waśkiel, A.; Olszewska, M.; Rudnicka, L. Intestinal barrier integrity in patients with plaque psoriasis. J. Dermatol. 2018, 45, 1468–1470. [Google Scholar] [CrossRef] [PubMed]
- Ogawa, E.; Owada, Y.; Ikawa, S.; Adachi, Y.; Egawa, T.; Nemoto, K.; Suzuki, K.; Hishinuma, T.; Kawashima, H.; Kondo, H.; et al. Epidermal FABP (FABP5) regulates keratinocyte differentiation by 13(S)-HODE-mediated activation of the NF-κB signaling pathway. J. Investig. Dermatol. 2011, 131, 604–612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Almeida, S.O.; Budoff, M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc. Med. 2019, 29, 451–455. [Google Scholar] [CrossRef]
- Oesterle, A.; Laufs, U.; Liao, J.K. Pleiotropic Effects of Statins on the Cardiovascular System. Circ. Res. 2017, 120, 229–243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trong, H.N.; Tat, T.N.; Anh, T.T.N.; Uyen, N.P.; Van, T.N.; Hau, K.T. Efficacy of adding oral simvastatin to topical therapy for treatment of psoriasis: The vietnamese experience. Open Access Maced. J. Med. Sci. 2019, 7, 237–242. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Okopień, B.; Buldak, L.; Bołdys, A. Fibrates in the management of atherogenic dyslipidemia. Expert Rev. Cardiovasc. Ther. 2017, 15, 913–921. [Google Scholar] [CrossRef] [PubMed]
- Imamura, T.; Takata, I.; Ogasawara, M.; Matsutani, Y.; Yamamoto, T.; Asagami, C. Clofibrate treatment of psoriasis with hypertriglycemia--clinical, histological and laboratory analysis. Nihon Hifuka Gakkai Zasshi 1991, 101, 623–628. [Google Scholar]
- Krahel, J.A.; Baran, A.; Kamiński, T.W.; Maciaszek, M.; Flisiak, I. Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. J. Clin. Med. 2020, 9, 910. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amoruso, G.F.; Nisticò, S.P.; Iannone, L.; Russo, E.; Rago, G.; Patruno, C.; Bennardo, L. Ixekizumab May Improve Renal Function in Psoriasis. Healthcare 2021, 9, 543. [Google Scholar] [CrossRef] [PubMed]
- Iannone, L.F.; Bennardo, L.; Palleria, C.; Roberti, R.; De Sarro, C.; Naturale, M.D.; Dastoli, S.; Donato, L.; Manti, A.; Valenti, G.; et al. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS ONE 2020, 15, e0241575. [Google Scholar] [CrossRef] [PubMed]
- Dattola, A.; Silvestri, M.; Tamburi, F.; Amoruso, G.F.; Bennardo, L.; Nisticò, S.P. Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising. Dermatol. Ther. 2020, 33, e14504. [Google Scholar] [CrossRef]
- Botelho, K.P.; Pontes, M.A.A.; Rodrigues, C.E.M.; Freitas, M.V.C. Prevalence of Metabolic Syndrome Among Patients with Psoriasis Treated with TNF Inhibitors and the Effects of Anti-TNF Therapy on Their Lipid Profile: A Prospective Cohort Study. Metab. Syndr. Relat. Disord. 2020, 18, 154–160. [Google Scholar] [CrossRef]
- Gerdes, S.; Pinter, A.; Papavassilis, C.; Reinhardt, M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 533–541. [Google Scholar] [CrossRef] [Green Version]
- Egeberg, A.; Wu, J.J.; Korman, N.; Solomon, J.A.; Goldblum, O.; Zhao, F.; Mallbris, L. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J. Am. Acad. Dermatol. 2018, 79, 104–109. [Google Scholar] [CrossRef] [Green Version]
- Cao, H.; Su, S.; Yang, Q.; Le, Y.; Chen, L.; Hu, M.; Guo, X.; Zheng, J.; Li, X.; Yu, Y. Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients. Lipids Health Dis. 2021, 20, 16. [Google Scholar] [CrossRef]
- Ryu, H.; Chung, Y. Regulation of IL-17 in atherosclerosis and related autoimmunity. Cytokine 2015, 74, 219–227. [Google Scholar] [CrossRef]
- Manti, S.; Leonardi, S.; Panasiti, I.; Arrigo, T.; Salpietro, C.; Cuppari, C. Serum IL-10, IL-17 and IL-23 levels as “bioumoral bridges” between dyslipidemia and atopy. Cytokine 2017, 99, 43–49. [Google Scholar] [CrossRef] [PubMed]
- Gelfand, J.M.; Shin, D.B.; Alavi, A.; Torigian, D.A.; Werner, T.; Papadopoulos, M.; Takeshita, J.; Noe, M.H.; Dey, A.K.; Playford, M.P.; et al. A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial). J. Investig. Dermatol. 2020, 140, 85–93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choi, H.; Uceda, D.E.; Dey, A.K.; Abdelrahman, K.; Aksentijevich, M.; Rodante, J.A.; Elnabawi, Y.A.; Reddy, A.; Keel, A.; Erb-Alvarez, J.; et al. Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core: Results From a Prospective, Observational Study. Circ. Cardiovasc. Imaging 2020, 13, e011199. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nowowiejska, J.; Baran, A.; Flisiak, I. Aberrations in Lipid Expression and Metabolism in Psoriasis. Int. J. Mol. Sci. 2021, 22, 6561. https://doi.org/10.3390/ijms22126561
Nowowiejska J, Baran A, Flisiak I. Aberrations in Lipid Expression and Metabolism in Psoriasis. International Journal of Molecular Sciences. 2021; 22(12):6561. https://doi.org/10.3390/ijms22126561
Chicago/Turabian StyleNowowiejska, Julia, Anna Baran, and Iwona Flisiak. 2021. "Aberrations in Lipid Expression and Metabolism in Psoriasis" International Journal of Molecular Sciences 22, no. 12: 6561. https://doi.org/10.3390/ijms22126561